- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05675072
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
A Phase II/III,Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Coronavirus Disease 2019 (COVID -19) is a respiratory illness that can spread from person to person. The infectious agent that causes COVID -19 is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), was first identified during a recent outbreak in December 2019, Patients with COVID-19 have symptoms of fever, cough, and shortness of breath along with non-specific symptoms including myalgia and fatigue.
FB2001 is a small-molecule inhibitor of coronavirus 3CL protease(3CLpro). In phase I clinical trial, FB2001 for Inhalation were safe and tolerable well in healthy subjects, and were projected to be effective in patients according to its pharmacokinetic profile.
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019 (COVID-19). The subjects will be randomized in a 1:1 ratio to FB2001 group or placebo group while both receiving standard of care treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Cheng Yao
- Email: yaocheng@frontierbiotech.com
Study Contact Backup
- Name: Yue Zhang
- Phone Number: +86 02569760330
- Email: lczhangyue@frontierbiotech.com
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China
- Recruiting
- Shenzhen Third People's Hospital
-
Contact:
- Dan Shu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years, male or female;
- Confirmed SARS-CoV-2 infection as determined by Reverse Transcription - Polymerase Chain Reaction(RT -PCR) in any specimen collected within 5 days prior to randomization.
Note: RT-PCR is the preferred method; however, with evolving approaches to laboratory confirmation of SARS-CoV-2 infection, other molecular or antigen tests that detect viral RNA or protein are allowed if authorized for use in the country;
- Patients with mild or moderate COVID-19.
- Initial onset of signs/symptoms attributable to COVID -19 within 3 days prior to the day of randomization and at least one of the specified signs/symptoms attributable to COVID -19 present on the day of randomization;
- Women of childbearing potential who have a negative serum or urine pregnancy test prior to the first study dose;
- Patient who is willing to cooperate and able to participate in the trial, adhered to all requirements of the protocol, and provided written informed consent.
Exclusion Criteria:
- Patients who are currently or are expected to potentially progress to severe/critical COVID-19 within 48 h of randomization;
- Patients with chronic respiratory diseases, including bronchial asthma and chronic obstructive pulmonary disease etc.
- Known history of moderate-severe liver impairment (e.g., Child-Pugh grade B or C, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 5x upper limit normal (ULN) , or acute liver failure within 6 months prior to screening;.
- Known history of severe renal impairment (e.g., Chronic Kidney Disease-Improved Prediction Equations(CKD-EPI)formula based on serum creatinine, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2), or was receiving renal replacement therapy, such as peritoneal dialysis or hemodialysis, within 6 months prior to screening;
- Impaired immune system (including patients treated with systemic corticosteroids or other immunosuppressive agents, or cancer progression or recurrence)
- Suspected or confirmed concurrent active systemic infections other than COVID-19 that may interfere with the assessment of response to study interventions.
- Need for radiotherapy, chemotherapy, emergency surgery or surgical treatment at screening, or other emergencies (e.g. acute coronary syndrome, acute pulmonary embolism, etc.).
- Patients with a history of cardiopulmonary resuscitation or major surgery within 30 days prior to randomization, and patients with other potentially life-threatening clinical conditions or other emergencies.
- History of hypersensitivity or other contraindications to any component of the study intervention.
- Patients who received or expected to receive anti-SARS-CoV-2 viral drugs (e.g., nirmatrelvir/ritonavir, molnupiravir, etc.) within 14 days prior to randomization.
- Have received (within 30 days prior to randomization or within 5 half-lives, whichever is longer) or expect to receive COVID-19 monoclonal antibody or recovery COVID-19 plasma therapy.
- Any SARS-CoV-2 vaccination within 3 months prior to randomization.
- Within 28 days or 5 half-lives (whichever is longer) prior to randomization or in clinical studies with other investigational drugs or devices, including studies for COVID-19.
- Mental illnesses that, in the judgment of the investigator, are not appropriate for participation in this study.
- Any other situation that the investigator believes may affect the subject's informed consent or adherence to the protocol, or the subject's participation in the study may affect the outcome of the study or his or her own safety, in the investigator's judgment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FB2001 group
FB2001 will be administered by nebulized inhalation, plus Standard Of Care(SOC)
|
FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation.
FB2001 will be administered by nebulized inhalation.
Other Names:
|
Placebo Comparator: Placebo group
Placebo will be administered by nebulized inhalation, plus Standard Of Care(SOC)
|
FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation.
FB2001 placebo will be administered by nebulized inhalation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to sustained recovery of COVID-19-related signs/symptoms
Time Frame: Up to Day 29
|
Sustained recovery of a COVID-19-related sign/symptom is defined as a COVID-19-related sign/symptom score of 0 for 3 consecutive days, i.e., disappearance of COVID-19-related symptoms or return to the status prior to the onset of COVID-19.
|
Up to Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants who have progression of COVID-19 .
Time Frame: Up to Day 29
|
Disease progression is defined as disease severity from mild to moderate or severe or critical, or moderate to severe or critical, or all-cause death
|
Up to Day 29
|
Time to sustained alleviation of COVID-19-related sign/symptom.
Time Frame: Up to Day 29
|
Sustained alleviation of COVID-19-related signs/symptoms are defined as the COVID-19-related sign/symptom score from 0 or 1 to 0 at baseline or from 2 or 3 to 1 or 0 at baseline for 3 consecutive days.
|
Up to Day 29
|
Time to sustained recovery of 5 key COVID-19-related sign/symptom
Time Frame: Up to Day 29
|
Sustained recovery of a COVID-19-related sign/symptom is defined as a COVID-19-related sign/symptom score of 0 for 3 consecutive days, i.e., disappearance of COVID-19-related symptoms or return to the status prior to the onset of COVID-19.
|
Up to Day 29
|
Time to sustained alleviation of 5 key COVID-19-related sign/symptom
Time Frame: Up to Day 29
|
Sustained alleviation of COVID-19-related signs/symptoms are defined as the COVID-19-related sign/symptom score from 0 or 1 to 0 at baseline or from 2 or 3 to 1 or 0 at baseline for 3 consecutive days.
|
Up to Day 29
|
Proportion of participants who experience sustained recovery of COVID-19 sign/symptom
Time Frame: Day 3 to Day 21
|
no special description
|
Day 3 to Day 21
|
Proportion of participants who experience sustained alleviation of COVID-19-related sign/symptom
Time Frame: Day 3 to Day 21
|
no special description
|
Day 3 to Day 21
|
Duration of each targeted COVID-19-related sign/symptom.
Time Frame: Up to Day 29
|
no special description
|
Up to Day 29
|
Time to sustained virus clearance of SARS-CoV-2 in nasopharyngeal swabs
Time Frame: Up to Day 29
|
no special description
|
Up to Day 29
|
Changes in SARS-CoV-2 viral load
Time Frame: Up to Day 29
|
no special description
|
Up to Day 29
|
Change in EQ-5D-5L index score
Time Frame: Up to Day 29
|
The Euroquol Quality of Life 5-Dimension 5-Level Scale(EQ-5D-5L) index score consists of five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression.
Each dimension has five scales: no difficulty, a little difficulty, moderate difficulty, severe difficulty, and very severe difficulty
|
Up to Day 29
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of Treatment-Emergent Adverse Events(TEAEs)
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Incidence of withdrawals due to Adverse Events(AEs)
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Incidence of Serious Adverse Events(SAEs)
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Safety as determined by abnormality in haematology
Time Frame: Up to Day 29
|
Measurement of white blood cell (WBC) count, red blood cell (RBC) count, haemoglobin (Hb), neutrophils absolute count, lymphocytes absolute count, monocytes absolute count, eosinophils absolute count, Platelets absolute count.
|
Up to Day 29
|
Safety as determined by abnormality in clinical chemistry
Time Frame: Up to Day 29
|
Measurement of sodium, potassium, urea/blood urea nitrogen (BUN), creatinine, albumin, calcium, phosphate, glucose, c-reactive protein (CRP), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), total bilirubin, conjugated bilirubin, creatine kinase.
|
Up to Day 29
|
Incidence of treatment-related grade 3 or above TEAEs
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Safety as determined by abnormality in urinalysis
Time Frame: Up to Day 29
|
Measurement of glucose, protein, blood and microscopy.
|
Up to Day 29
|
Safety as determined by abnormality in Coagulation.
Time Frame: Up to Day 29
|
Measurement of international normalised ratio (INR), prothrombin time, activated partial thrombin time (aPTT).
|
Up to Day 29
|
Incidence of treatment-related adverse events (TRAEs)
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Incidence of discontinuation of study treatment due to TEAEs
Time Frame: Up to Day 29
|
safety evaluation
|
Up to Day 29
|
Incidence of abnormal 12-lead electrocardiogram (ECG)
Time Frame: Up to Day 29
|
Results for P wave PR interval, QRS duration, QT interval, QTcF interval, RR interval, and heart rate will be analyzed.
|
Up to Day 29
|
Safety as determined by abnormal vital signs (blood pressure, pulse rate, body temperature, and respiratory rate)
Time Frame: Up to Day 29
|
Measurement of systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), pulse rate (beats per minute), body temperature (in degree Celsius), respiratory rate (breaths per minute).
|
Up to Day 29
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cheng Yao, Frontier Biotechnologies Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FB2001-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild to Moderate COVID-19
-
Károli Gáspár University of the Reformed Church...University of TorontoCompletedMild to Moderate Psychopathological SymptomsHungary
-
Károli Gáspár University of the Reformed Church...University of TorontoCompletedMild to Moderate Psychopathological SymptomsHungary
-
NestléCompletedMild to Moderate Levels of StressSwitzerland
-
Tishreen UniversityCompletedMild to Moderate Anterior Mandibular Segment CrowdindSyrian Arab Republic
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationCompletedMild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital RhytidsUnited States
-
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.RecruitingMild to Moderate COVID-19China
-
Ology BioservicesPharm-Olam, LLC; Chemical, Biological, Radiological, and Nuclear MedicalWithdrawnMild to Moderate COVID-19
-
Kaleido BiosciencesCompletedMild-to-Moderate COVID-19United States
-
Kaleido BiosciencesCompletedMild-to-moderate COVID-19United States
-
Oneness Biotech Co., Ltd.RecruitingMild to Moderate COVID-19Taiwan, United States
Clinical Trials on FB2001
-
Frontier Biotechnologies Inc.Recruiting
-
Frontier Biotechnologies Inc.Completed
-
Frontier Biotechnologies Inc.Completed
-
Frontier Biotechnologies Inc.Completed
-
Ruijin HospitalFrontier Biotechnologies Inc.; Shanghai Center for Disease Control and PreventionNot yet recruitingClose Contact Transmission